{
    "clinical_study": {
        "@rank": "129560", 
        "acronym": "CJCV1-01", 
        "arm_group": [
            {
                "arm_group_label": "CJCV1 2 \u03bcg / Alum 0 \u03bcg (1A)", 
                "arm_group_type": "Experimental", 
                "description": "Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 \u03bcg of polysaccharide and 0 \u03bcg of Alhydrogel\u00ae, aluminum hydroxide adjuvant (Alum)"
            }, 
            {
                "arm_group_label": "CJCV1 2 \u03bcg / Alum 125 \u03bcg (1B)", 
                "arm_group_type": "Experimental", 
                "description": "Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 \u03bcg of polysaccharide and 125 \u03bcg of Alhydrogel\u00ae, aluminum hydroxide adjuvant (Alum)"
            }, 
            {
                "arm_group_label": "CJCV1 5 \u03bcg / Alum 0 \u03bcg (2A)", 
                "arm_group_type": "Experimental", 
                "description": "Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 \u03bcg of polysaccharide and 0 \u03bcg of Alhydrogel\u00ae, aluminum hydroxide adjuvant (Alum)"
            }, 
            {
                "arm_group_label": "CJCV1 5 \u03bcg / Alum 125 \u03bcg (2B)", 
                "arm_group_type": "Experimental", 
                "description": "Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 \u03bcg of polysaccharide and 125 \u03bcg of Alhydrogel\u00ae, aluminum hydroxide adjuvant (Alum)"
            }, 
            {
                "arm_group_label": "CJCV1 10 \u03bcg / Alum 0 \u03bcg (3A)", 
                "arm_group_type": "Experimental", 
                "description": "Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 \u03bcg of polysaccharide and 0 \u03bcg of Alhydrogel\u00ae, aluminum hydroxide adjuvant (Alum)"
            }, 
            {
                "arm_group_label": "CJCV1 10 \u03bcg / Alum 125 \u03bcg (1A)", 
                "arm_group_type": "Experimental", 
                "description": "Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 \u03bcg of polysaccharide and 125 \u03bcg of Alhydrogel\u00ae, aluminum hydroxide adjuvant (Alum)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety of increasing doses of a potential vaccine\n      against Campylobacter with and without Alhydrogel\u00ae, an aluminum hydroxide adjuvant. This\n      study will also assess immune responses induced by the vaccine."
        }, 
        "brief_title": "Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Campylobacter Infection", 
        "condition_browse": {
            "mesh_term": "Campylobacter Infections"
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, dose-escalating study in which a total of 48 healthy volunteers will\n      receive 2 vaccinations (one on Day 0 and one on Day 28 \u00b1 2 days).\n\n      There are 3 cohorts (dose levels) with 2 groups of 8 volunteers in each cohort. A cohort\n      will be administered one of 3 intramuscular (IM) doses at 2 \u03bcg, 5 \u03bcg, or 10 \u03bcg of\n      Capsule-Conjugate Campylobacter Vaccine (CJCV1) with or without Alhydrogel\u00ae, aluminum\n      hydroxide adjuvant (alum) at 125 \u03bcg.\n\n      An interval no less than 1 week will separate the last dose of a volunteer group from the\n      first dose of the next volunteer group (receiving different CJCV1 doses). Blood specimens\n      will be collected at intervals to examine systemic and mucosal antigen-specific immune\n      responses. Vaccine safety will be actively monitored during vaccination and for 28 days (\u00b1 2\n      days) following the second vaccination and complete the study with a telephone follow-up\n      approximately 6 months (\u00b1 1 month) after the first vaccination. The total duration of\n      participation in this study is up to 270 days (including screening)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adult, male or female, age 18 to 50 years (inclusive) at the time of\n             enrollment.\n\n          -  Completion and review of comprehension test (achieved 70% accuracy).\n\n          -  Signed informed consent document.\n\n          -  Available for the required follow-up period and scheduled clinic visits and telephone\n             follow-up.\n\n          -  Women:  Negative pregnancy test with understanding (through informed consent) to not\n             become pregnant during the study or within three months after the last vaccine dose\n             (Day 28). Sexually active females, unless surgically sterile or at least one year\n             postmenopausal, must have used an effective method of avoiding pregnancy (including\n             oral or implanted contraceptives, intrauterine device (IUD), female condom, diaphragm\n             with spermicide, cervical cap, abstinence, use of a condom by the sexual partner, or\n             sterile sexual partner) prior to dosing of study vaccine. Female subjects unable to\n             bear children must have a note from a primary care provider or obstetrics and\n             gynaecology (OB/GYN) as proof of documentation (eg, tubal ligation or hysterectomy).\n             If a volunteer becomes pregnant during the study, the PI will notify the study\n             monitor, the sponsor, and the local institutional review board (IRB). The volunteer\n             will be asked to provide serial follow-ups, including copies of clinic visits on the\n             status of her pregnancy as well as health information on her infant following\n             delivery.\n\n        Exclusion Criteria:\n\n          -  Health problems, for example, chronic medical conditions such as psychiatric\n             conditions, diabetes mellitus, hypertension, or any other condition requiring daily\n             therapy that would place a subject at increased risk of AEs. Study clinicians, in\n             consultation with the PI, will use clinical judgment on a case-by-case basis to\n             assess safety risks under this criterion. The PI will consult with the research\n             monitor as appropriate.\n\n          -  Clinically significant abnormalities on physical examination.\n\n          -  Use of immunosuppressive medications, such as corticosteroids and chemotherapy,\n             during the course of the study or immunosuppressive illness, including IgA deficiency\n             (defined by serum IgA below level of detection).\n\n          -  Women who are pregnant or planning to become pregnant during the study period plus 3\n             months beyond the last vaccine dose and currently nursing women.\n\n          -  Participation in research involving another investigational product 30 days before\n             the planned date of first vaccination or anytime through the last study safety visit.\n\n          -  Positive blood test for HBsAg, anti-hepatitis C virus (HCV) antibody, HIV-1.\n\n          -  Clinically significant abnormalities on basic laboratory screening.\n\n          -  Presence of significant unexplained laboratory abnormalities that, in the opinion of\n             the PI, may potentially confound the analysis of the study results.\n\n          -  Regular use (weekly or more often) of anti-diarrheal, anti-constipation, or antacid\n             therapy.\n\n          -  Abnormal bowel habits as defined by fewer than 3 stools per week or more than 3\n             loose/liquid stools per day.\n\n          -  Personal or family history of an inflammatory arthritis.\n\n          -  Personal history of irritable bowel syndrome.\n\n          -  Positive blood test for Human Leukocyte Antigen (HLA)-B27.\n\n          -  History of allergy to any vaccine.\n\n          -  History of allergy to alum.\n\n          -  History of travelers' diarrhea or residence (> 2 months) in the past 3 years in a\n             country with potentially higher Campylobacter rates to include Africa, South America,\n             Central America, and Asia (except Japan).\n\n          -  Occupation involving handling of Campylobacter bacteria or vaccine products currently\n             or in the past 3 years.\n\n          -  History of microbiologically confirmed Campylobacter infection.\n\n          -  Received previous experimental Campylobacter vaccine or live Campylobacter challenge."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02067676", 
            "org_study_id": "S-13-09", 
            "secondary_id": "NMRC.2013.0021"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CJCV1 2 \u03bcg / Alum 0 \u03bcg (1A)", 
                    "CJCV1 2 \u03bcg / Alum 125 \u03bcg (1B)", 
                    "CJCV1 5 \u03bcg / Alum 0 \u03bcg (2A)", 
                    "CJCV1 5 \u03bcg / Alum 125 \u03bcg (2B)", 
                    "CJCV1 10 \u03bcg / Alum 0 \u03bcg (3A)", 
                    "CJCV1 10 \u03bcg / Alum 125 \u03bcg (1A)"
                ], 
                "description": "The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)", 
                "intervention_name": "Capsule-Conjugate Campylobacter Vaccine (CJCV1)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "CJCV1 2 \u03bcg / Alum 125 \u03bcg (1B)", 
                    "CJCV1 5 \u03bcg / Alum 125 \u03bcg (2B)", 
                    "CJCV1 10 \u03bcg / Alum 125 \u03bcg (1A)"
                ], 
                "intervention_name": "Alhydrogel\u00ae, aluminum hydroxide adjuvant (alum)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aluminum Hydroxide", 
                "Aluminum sulfate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Campylobacter jejuni", 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Silver Spring", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20910"
                }, 
                "name": "Walter Reed Army Institute of Research"
            }, 
            "investigator": [
                {
                    "last_name": "Ramiro L Gutierrez, MD, MPH", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mark S Riddle, MD, DrPH", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kristopher M Paolino, MD, MTM&H", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Chad Porter, PhD, MPH", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Patricia Guerry, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Alexander Maue, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Robert Gormley, MD, PhD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "Safety and Immunogenicity Evaluation of an Intramuscular Capsule-Conjugate Campylobacter Vaccine (CJCV1)", 
        "overall_contact": {
            "email": "robert.gormley@med.navy.mil", 
            "last_name": "Robert Gormley, MD, PhD", 
            "phone": "301-319-7312"
        }, 
        "overall_official": {
            "affiliation": "Enteric Disease Department, Naval Medical Research Center", 
            "last_name": "Robert Gormley, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Vaccine safety will be assessed by evaluating post-vaccination local and systemic reactions through targeted physical exams, symptom surveys, and other adverse event (AE) monitoring. All subjects will be observed in the clinic for at least 30 minutes after receipt of the investigational product. Approximately 48 hours after vaccination, subjects will return to the Clinical Trials Center for observation and reporting of any local and/or systemic AEs. Seven days after vaccine administration, subjects will return to the Clinical Trials Center to review their memory aids with study personnel and to report any AEs. In addition to planned visits, if a subject experiences any unanticipated AE, the subject will be seen by one of the study investigators. All AEs will be coded for onset date, duration, severity, and potential relationship to the investigational product.", 
            "measure": "Presence of local and/or systemic reactogenicity", 
            "safety_issue": "Yes", 
            "time_frame": "up to  7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02067676"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The antibody titer assigned to each sample will represent the geometric mean of duplicate tests performed on 2 different days. Reciprocal endpoint titers < 5 will be assigned a value of 2.5 for computational purposes. Seroconversion will be defined as a > fourfold increase in endpoint titer between pre- and post-vaccination samples and post-vaccination reciprocal titer > 10.", 
                "measure": "Antibody titers against CJCV1 using enzyme-linked immunosorbent assay (ELISA)", 
                "safety_issue": "No", 
                "time_frame": "Study Days 0-56"
            }, 
            {
                "description": "A positive immunoglobulin A (IgA)-ASC response will be defined as a > twofold increase over the baseline value of the ASCs per 10^6 peripheral blood mononuclear cells (PBMCs). A subject will be considered a responder if the post-vaccination value is greater than 2.0 per 10^6 PBMCs. Blood samples will also be utilized to explore in vitro production of interferon (IFN)-(gamma).", 
                "measure": "Vaccine-specific IgA antibody-secreting cell (ASC) responses", 
                "safety_issue": "No", 
                "time_frame": "Study Days 0-56"
            }
        ], 
        "source": "U.S. Army Medical Research and Materiel Command", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "U.S. Army Medical Research and Materiel Command", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}